Janssen GPH will also prioritise
work with the International Partnership for Microbicides developing the investigational drug dapivirine for use as a monthly vaginal microbicidal ring designed to prevent sexual transmission of HIV and
continue its pact with Drugs for Neglected Diseases initiative for the
preclinical research of a reformulated form of flubendazole for lymphatic filariasis (elephantiasis) and onchocerciasis (river blindness), Janssen GPH is also developing a new, chewable formulation of Vermox (mebendazole) that will facilitate treatment of intestinal worms in younger children.